Can I Take Creatine with Egrifta (Tesamorelin)?
Key numbers
- 0.14 mg/dLAverage rise in serum creatinine from creatine across 26 studiesSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 10.75 mL/minAverage fall in creatinine-based GFR from creatine in the 26-study analysisSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1.4 mgEgrifta SV dose, injected once daily under the skin of the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 3 to 5 g/dayMaintenance creatine dose per day in NIH ODS adult study protocolSource: ods.od.nih.gov, as cited Nov 7, 2026
At a glance
- Drug / tesamorelin: Egrifta SV 1.4 mg or Egrifta WR 1.28 mg, subcutaneous once daily [1][2]
- Supplement / creatine monohydrate, study protocols of 3 to 5 g/day maintenance, or 3 to 6 g/day with no loading phase [5]
- Label interaction listing / CYP450-metabolized drugs and glucocorticoids; creatine is not named in either label [1][2]
- Creatine effect on serum creatinine / +0.13 to 0.14 mg/dL average, no change in Cr-EDTA-measured GFR [3][4]
- Tesamorelin monitoring per label / IGF-1 and glucose [1]
- Creatine side effects per NIH ODS / no consistent set except weight gain from water retention, about 1 to 2 kg in a month with strength training [5]
- Creatine in kidney trials / no loss of filtration in trained adults, adults with type 2 diabetes, and sedentary men [6][7][8]
What Egrifta Is and What the Label Covers
Tesamorelin is a synthetic analog of human growth hormone-releasing factor. It binds and stimulates GRF receptors on pituitary somatotroph cells, which release more of the body's own growth hormone, and that raises IGF-1 and IGFBP-3 [1]. Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously into the abdomen once daily, rotating sites [1]. Egrifta WR is 1.28 mg (0.16 mL) on the same schedule, and the labels state the two products are not substitutable [2].
The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it is not indicated for weight loss because the effect on weight is neutral, and that long-term cardiovascular safety has not been established [1].
The Egrifta Drug Interactions Section, in Full
The label lists two interaction entries. The first covers drugs metabolized by CYP450 liver enzymes: published data suggest growth hormone may alter their clearance, and the label names corticosteroids, sex steroids, anticonvulsants and cyclosporine and asks prescribers to monitor [1]. Coadministration with simvastatin changed simvastatin exposure by about -8% (AUC) and ritonavir exposure by about -9%, which the label calls no significant impact [1]. The second covers glucocorticoids: growth hormone inhibits 11-beta-HSD1, so the label says people receiving glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting Egrifta [1].
Creatine appears in neither entry, in either label [1][2]. It is sold over the counter as a dietary supplement, and a Drugs@FDA search returns no approved drug application with creatine as the active ingredient [5][9].
The Creatinine Question
Creatine is not creatinine, but the body converts one into the other, and creatinine is the waste product standard kidney blood tests measure [4]. Pooled randomized trials put the average rise in serum creatinine at 0.13 mg/dL (19 RCTs plus one crossover study; 95% CI 0.07 to 0.18) [3] and 0.14 mg/dL (26 studies, 1,036 people; 95% CI 0.05 to 0.22) [4].
In the 26-study analysis, creatinine-based GFR fell by an average of 10.75 mL/min (95% CI -17.48 to -4.02), while GFR measured by Cr-EDTA did not change significantly (+5.89 mL/min, 95% CI -0.30 to 12.08); urea, albuminuria and proteinuria were unchanged [4]. The authors read the pattern as altered creatinine metabolism rather than kidney injury [4].
Trials that measured filtration directly point the same way. In resistance-trained adults eating at least 1.2 g/kg/day of protein, 12 weeks of creatine (20 g/day for 5 days, then 5 g/day) gave 51Cr-EDTA clearance of 101.4 to 108.8 mL/min/1.73 m2 versus 103.3 to 106.7 on placebo (group-by-time p=0.64) [6]. In adults with type 2 diabetes over 12 weeks, 51Cr-EDTA clearance was 90.4 to 96.1 on creatine versus 97.9 to 96.4 on placebo (p=0.58), with proteinuria and albuminuria unchanged [7]. In 18 sedentary men taking about 10 g/day for 3 months, cystatin C fell on both creatine and placebo, showing no sign of reduced filtration [8]. One case report describes a 24-year-old weightlifter who developed biopsy-proven acute interstitial nephritis while taking creatine plus several other supplements and recovered fully after stopping all of them; creatine cannot be singled out [12].
The practical point: a creatinine-based eGFR can under-read kidney function in someone taking creatine, so whoever orders the kidney panel should know creatine is in use [4].
Questions worth asking
Kidney Function and Tesamorelin
The monitoring tests the Egrifta labels single out are IGF-1 and glucose [1][2]. The labels also state that tesamorelin pharmacokinetics in people with renal or hepatic impairment have not been established [1][2].
What the Label Asks Prescribers to Watch
IGF-1 is the main one. Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3; at 52 weeks, the figures were 34% and 23% [1]. The label asks prescribers to monitor IGF-1 and consider stopping for persistent elevations such as above 3 SDS, particularly if the fat reduction is not robust [1].
Glucose is the second. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26 (hazard ratio about 3.3, 95% CI 1.4 to 9.6), and the label calls for evaluating glucose before and during treatment [1].
Fluid retention is a labeled warning and shows up as edema, joint pain and carpal tunnel syndrome [1]. Injection site reactions occurred in 25% on tesamorelin versus 14% on placebo in the first 26 weeks [1]. Hypersensitivity reactions occurred in 4%, and the label says to seek prompt medical attention and discontinue treatment if one is suspected [1].
Creatine has a different kind of water-related effect. NIH ODS reports no consistent set of side effects except weight gain from water retention, about 1 to 2 kg in a month when creatine is combined with strength training [5].
Creatine and Growth Hormone
In 11 men, five days of creatine at 20 g/day did not change the growth hormone or testosterone response to a heavy resistance-training session [13]. That study measured growth hormone, testosterone and cortisol responses, not IGF-1. In the 412-patient tesamorelin trial, IGF-1 rose 81.0% on tesamorelin versus a 5.0% fall on placebo over 26 weeks [10].
Dosing
NIH ODS describes two creatine monohydrate study protocols in adults: a loading phase of 20 g/day in four 5 g portions for 5 to 7 days followed by 3 to 5 g/day, or about 3 to 6 g/day for 3 to 4 weeks without a loading phase [5].
The International Society of Sports Nutrition position stand calls short- and long-term supplementation, up to 30 g/day for 5 years, safe and well tolerated in healthy people and some patient groups. That is a society position paper, not a regulator's finding [14].
Egrifta is dosed by its own label: SV 1.4 mg once daily or WR 1.28 mg once daily, both into the abdomen with site rotation, and the two products are not interchangeable [1][2].
Creatine monohydrate is the form with the most research [5]; unflavored creatine monohydrate powder is one example.
Kidney Disease, Heat and Other Limits
Few creatine trials enrolled people with kidney disease, and long-term safety in advanced kidney disease is not established by these data [4]. In a heat-stress trial, 12 active men who took 21.6 g/day for 7 days, lost 2% of body mass and then completed an 80-minute exercise test at 33.5 C had no difference in rectal temperature (39.3 vs 39.4 C) or other thermoregulatory responses compared with placebo [15].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Can I take creatine with Egrifta (tesamorelin)?
Will creatine make my creatinine look high while on tesamorelin?
Does creatine change growth hormone or IGF-1?
Is creatine hard on the kidneys?
Is a creatine loading phase required?
References
Show all 15 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Tsiaras A, Loufopoulos G, Theodoridis X, Liakopoulos V, Poulia KA, Chourdakis M. The Effect of Creatine Supplementation on Kidney Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Ren Nutr. 2026.
- de Souza Almeida A, da Silva LOD, Takahasi BNA, Terada BD, Gonçalves FGA, Porto BC, et al. Impact of creatine supplementation on kidney health: a systematic review and meta-analysis. Int Urol Nephrol. 2026.
- National Institutes of Health.
- Lugaresi R, Leme M, de Salles Painelli V, Murai IH, Roschel H, Sapienza MT, et al. Does long-term creatine supplementation impair kidney function in resistance-trained individuals consuming a high-protein diet?. J Int Soc Sports Nutr. 2013;10(1):26.
- Gualano B, de Salles Painelli V, Roschel H, Lugaresi R, Dorea E, Artioli GG, et al. Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Eur J Appl Physiol. 2011;111(5):749-56.
- Gualano B, Ugrinowitsch C, Novaes RB, Artioli GG, Shimizu MH, Seguro AC, et al. Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial. Eur J Appl Physiol. 2008;103(1):33-40.
- Drugs@FDA: FDA-Approved Drugs.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
- Thorsteinsdottir B, Grande JP, Garovic VD. Acute renal failure in a young weight lifter taking multiple food supplements, including creatine monohydrate. J Ren Nutr. 2006;16(4):341-5.
- Eijnde BO, Hespel P. Short-term creatine supplementation does not alter the hormonal response to resistance training. Med Sci Sports Exerc. 2001;33(3):449-53.
- Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14:18.
- Watson G, Casa DJ, Fiala KA, Hile A, Roti MW, Healey JC, et al. Creatine use and exercise heat tolerance in dehydrated men. J Athl Train. 2006;41(1):18-29.